[{"id":"3288853e-96f2-4dd9-bec9-3877609dd1ea","acronym":"ORIOn-E","url":"https://clinicaltrials.gov/study/NCT03525795","created_at":"2021-01-18T17:23:07.841Z","updated_at":"2025-02-25T15:43:04.235Z","phase":"Phase 1","brief_title":"ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03525795 - ORIOn-E","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • lirametostat (CPI-1205)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 06/12/2019","primary_completion_date":" 06/12/2019","study_txt":" Completion: 06/12/2019","study_completion_date":" 06/12/2019","last_update_posted":"2022-05-18"}]